MediciNova is a biopharmaceutical company based in San Diego, CA, dedicated to developing innovative therapies for neurology, respiratory, and liver diseases that currently lack effective treatment options.
Their development pipeline includes MN-166, targeting progressive multiple sclerosis and amyotrophic lateral sclerosis (ALS); MN-221, focused on acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD); and MN-001, addressing fibrotic diseases such as liver fibrosis, non-alcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF).
Generated from the website